Please login to the form below

Not currently logged in
Email:
Password:

Manish Singh resigns as CEO of ImmunoCellular Therapeutics

Replaced on interim basis by company chair and chief scientific officer Dr John Yu

John Yu - ImmunoCellularDr Manish Singh has stepped down as CEO of ImmunoCellular Therapeutics to be replaced by the company's founder Dr John Yu (pictured) on an interim basis.

US-based cancer specialist ImmunoCellular said that Dr Singh has left to "pursue other opportunities" having joined as president and CEO of the company in February 2008.

In that time, the company has focused on its lead candidate ICT-107, a cell-based vaccine in phase II development to target glioblastoma brain tumours.

The drug's progress will now be overseen by Dr Yu, who asserted his confidence in the treatment's potential, as well as ImmunoCellular's other pipeline products.

“We hope that this trial will provide clinical validation of our platform and represent a potential breakthrough treatment for this deadly and intractable cancer," he said.

“We intend to continue to make progress in advancing our earlier stage product candidates, with the recent approval of an IND to initiate a phase I trial of ICT-121 targeting CD133-positive cancer stem cells. We are developing a phase I study with ICT-140 to treat ovarian cancer.”

Dr Yu is the chief scientific officer and chair of ImmunoCellular in addition to serving on the faculty of the Department of Neurosurgery at Cedars-Sinai Medical Center.

He will continue as interim CEO while a search for a permanent replacement for Dr Singh is carried out.

22nd August 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics